New obesity drug candidate enters early human testing

NCT ID NCT06606106

Ongoing Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called LY3537031 in overweight, obese, and healthy volunteers. The main goal is to check safety and how the body handles the drug. Researchers will also measure weight changes and blood sugar levels. The study involves about 300 people and lasts up to 49 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3537031 (a drug given as an injection under the skin)
What this could lead to: If this early study shows the drug is safe and leads to weight loss, it could point toward a new treatment for obesity.
What could go wrong: This is a very early Phase 1 trial, so the main goal is safety, not weight loss. The drug may not work or could have side effects. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY OBESITY OVERWEIGHT

Contacts and locations

Locations

Clinical Pharmacology of Miami

Miami, Florida, 33172, United States
Collaborative Neuroscience Research, LLC

Los Alamitos, California, 90720, United States
Fortrea Clinical Research Unit

Daytona Beach, Florida, 32117, United States
Fortrea Clinical Research Unit

Dallas, Texas, 75247, United States
QPS

Springfield, Missouri, 65802, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.